The management of multiple sclerosis (MS) is changing, and for the fir
st time treatments which appear to influence the course of the disease
are becoming available. This article examines our current understandi
ng of MS pathogenesis and assesses which, if any, of the emerging ther
apies are likely to make an impact on this potentially disabling condi
tion.